CHAMGAP
Verdict No. 1878 · Search date 2026-07-24 · Methodology v1.0

Robot-assisted upper-limb training,
does it really help with Superior arm-function recovery after stroke compared with usual rehabilitation?

30-Second Summary
D
Evidence Grade D · 34 · Safety acceptable
Legacy grade under review
The robot delivers repetitive practice but did not outperform usual rehabilitation for arm recovery
Robot-assisted upper-limb training is generally safe when supervised. Fatigue, pain, or increased muscle tightness should prompt adjustment of intensity and repetitions.
What the
research shows
The claim that robot-assisted training produces better post-stroke arm recovery than usual rehabilitation is rated D with 34 points. Assessor-masked RATULS randomized 770 participants and included 669 in the three-month primary analysis, leaving 101 missing outcomes (13.1%). Action Research Arm Test success was 44% versus 42%, adjusted odds ratio 1.17 (98.3% CI 0.70 to 1.96), so the primary outcome failed. Positive pooled findings from smaller trials may reflect small-study and publication effects, so the large independent confirmatory trial takes priority.
What the
ads claim
The factual ability to deliver more repetitive movements should not be expanded into superior everyday functional recovery. RATULS also found no superiority over enhanced upper-limb therapy.
*

Useful facts when choosing a product

  • The MIT-Manus system in RATULS used shoulder-elbow, wrist, and hand modules to provide repeated movements.
  • The robotic group was assigned 45-minute sessions three times weekly for 12 weeks, totaling 36 sessions. Delivery of repetitions is factual; superior recovery is a separate clinical question.
  • The 770 randomized participants must be distinguished from the 669 with primary three-month outcome data.
ID

Chamgap Semantic Classification Code

Candidate index · review held

X.robot-assisted-upper-limb-training-using-the-mit-manus-repetitive-rehabilitation-system.behavioral.superior-arm-function-recovery-after-stroke.superiority.UNK

Behaviors, exposures and policies > Robot-assisted upper-limb training using the MIT-Manus repetitive-rehabilitation system > Behavioral delivery > Superior arm-function recovery after stroke > Superiority claim > Unknown

An automated migration candidate, not an issued permanent code; exact claim scope remains under review. This machine-generated migration candidate helps retrieval but is not a permanent assignment. The original verdict ID and URL remain authoritative.

Download semantic index (JSON) · Codebook v1

01

What the research actually shows

Assessor-masked RATULS randomized 770 participants and included 669 in the three-month primary analysis, leaving 101 missing outcomes (13.1%). Action Research Arm Test success was 44% versus 42%, adjusted odds ratio 1.17 (98.3% CI 0.70 to 1.96), so the primary outcome failed. The 2018 Mehrholz Cochrane review found arm-function SMD 0.32 (95% CI 0.18 to 0.46), I-squared 36%, P<0.0001 across 41 trials and 1,452 participants, and activities-of-daily-living SMD 0.31 (95% CI 0.09 to 0.52), I-squared 59% across 24 trials and 957 participants. When pooled small trials and a large independent trial differ, the confirmatory trial takes priority rather than being labeled repeated conflict. Verdict 1879 is currently listed as C with 50 points because virtual reality lacks a comparable large confirmatory trial and its updated pooled evidence varies; robotics has RATULS, and RATULS failed.

02

Why this is classified as D (34)

The patient-function primary outcome failed in large, publicly funded RATULS, which takes priority over pooled small-study signals. No major bias defect is counted, but the upper confidence limit of 1.96 still allows a large benefit, giving D with 34 points.

Counterpoint. The system may help deliver additional practice to selected patients. This verdict addresses claimed clinical superiority over usual or purpose-matched rehabilitation.

Rejudgment record. Cross-check applied — Priority given to the failed patient-function primary outcome in large publicly funded RATULS, with earlier small-study signals plausibly reflecting small-study and publication effects and a confidence interval that still permits benefit

Stored scoring profile
EndpointPSymptom or function itself is the target - including patient reports and performance tests
ReplicationR1Single confirmatory trial
IndependenceI2Decisive evidence is publicly or non-profit funded
Effect sizeE0Null
PrecisionC0The confidence interval leaves room for benefit

Stored derived and displayed grades match; this is not a current recalculation or validity check (D).

Sub-claim grades by effect

This ingredient is marketed for several effects. A single overall grade blends strong and weak claims together, so each effect is graded separately here. The overall grade reflects the strongest disconfirming or core claim.

Effect (sub-claim)GradeBasis
Increased three-month arm-function success versus usual careDAction Research Arm Test success was 44% versus 42%, adjusted odds ratio 1.17, and failed.
Superior arm function versus enhanced upper-limb therapyDThe adjusted odds ratio was 0.78 and did not show superiority.
Improved activities of daily livingCAn earlier small-trial meta-analysis found SMD 0.31, but this was not aligned with the large trial.
03

Evidence Table

StudyDesignSampleFundingEndpointResultWeight
Rodgers H et al. 2019 (RATULS)Multicenter pragmatic randomized assessor-masked three-group trial770 randomized; 669 in the actual three-month primary analysisPublic funding from the United Kingdom NIHR Health Technology Assessment ProgrammeThree-month Action Research Arm Test upper-limb function successThe primary outcome failed: 44% versus 42%, adjusted odds ratio 1.17 (98.3% CI 0.70 to 1.96).Decisive large independent null trial
Mehrholz J et al. 2018Cochrane systematic review and meta-analysis41 trials and 1,452 participants for arm function; 24 trials and 957 participants for activities of daily livingAcademic Cochrane review; funding varied across included trialsActivities of daily living, arm function, and strengthArm-function SMD 0.32 (95% CI 0.18 to 0.46), I-squared 36%, P<0.0001; activities-of-daily-living SMD 0.31 (95% CI 0.09 to 0.52), I-squared 59%.Earlier positive pooled signal from small trials
§

Receipt — 2 References

Retained evidence-access date: 2026-07-24. This correction checked record consistency; it did not reverify every original source or recertify the grade.

Rodgers H, Bosomworth H, Krebs HI, et al. Robot assisted training for the upper limb after stroke (RATULS): a multicentre randomised controlled trial. Lancet. 2019;394(10192):51-62. PMID: 31128926. PMCID: PMC6620612. DOI: 10.1016/S0140-6736(19)31055-4.
Retained record · not newly source-verified
Mehrholz J, Pohl M, Platz T, Kugler J, Elsner B. Electromechanical and robot-assisted arm training for improving activities of daily living, arm function, and arm muscle strength after stroke. Cochrane Database Syst Rev. 2018;2018(9):CD006876. DOI: 10.1002/14651858.CD006876.pub5.
Retained record · not newly source-verified
Codex compared retained study and verdict records with ChatGPT's methodological consistency review. No new literature search, full-text acquisition, or external expert review was performed.
This correction by: Codex · Evidence date: 2026-07-24 · Corrections: 1

Correction log — 1

Corrections applied to this verdict, in chronological order. Changes are logged, not erased.

  • 2026-09-14 · Editorial correction and legacy-grade review notice — Corrected the English cross-reference to verdict 1879 from 45 to its stored score of 50. Grade and score are retained, not certified as a new final assessment. (grade D unchanged)

Cite the review status too

Legacy grade under review. New grade-card distribution is on hold.

[Chamgap] Robot-assisted upper-limb training x superior arm-function recovery after stroke — legacy D · 34, under review. https://chamgap.com/en/verdicts/cognition/robot-assisted-upper-limb-training-stroke-functional-recovery/ · CC BY 4.0
!

What this document does and does not do

Chamgap is an information source. It reports what research has and has not confirmed; it does not tell readers what to take or buy. That decision belongs to readers and, when needed, medical or legal professionals. This verdict reflects literature available up to the search date and may change as new research appears. Nothing here is medical advice.